REMAP-CAP is led by the world’s leading critical care trialists and experts in pandemic and infectious disease outbreaks, virology, immunology, emergency medicine, and Bayesian statistics. REMAP-CAP ...
It’s unlikely that adding an antiplatelet agent to anticoagulation will increase the number of organ support-free days in critically ill patients with COVID-19, although it’s possible that survival in ...
CHESTERBROOK, Pa., April 21, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ...
Intravenous vitamin C did little to increase days free of organ support in adult patients hospitalized with COVID-19, two harmonized clinical trials known as LOVIT-COVID and REMAP-CAP found. Among ...
The world’s largest trial of multiple interventions for critically ill adults with COVID-19 has simultaneously released results about two of its treatments, vitamin C and simvastatin LARKSPUR, Calif. ...
NovaBiotics' NM002 (cysteamine bitartrate) Under Investigation in a Phase 3 Study for Community Acquired Pneumonia, Including COVID-19, Influenzas and Bacterial Pneumonias REMAP-CAP is a global ...
The world’s largest trial of multiple interventions for critically ill adults with COVID-19 has simultaneously released results about two of its treatments, vitamin C and simvastatin Simvastatin, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results